Work Package 2: GLIORESIST

Project 9: Systems-based integration and analysis of a deeply phenotyped GBM cohort correlating to 'extreme' and 'poor' responding patients

Location: Royal College of Surgeons in Ireland

Principle Investigator: Prof Jochen Prehn

Collaborators: Dr Alexander Kel (geneXplain, Germany), Dr Ahmed Idbaih (ICM Institute for Brain and Spinal Cord, France)

Project 10: Multi-scale mathematical modelling of non-Darwinian dynamics in therapy-induced drug resistance in GBM

Location: Royal College of Surgeons in Ireland

Principle Investigator: Dr Marc Sturrock

Collaborators: Dr Alexander Kel (geneXplain, Germany)

Project 11: Single-cell RNA-sequencing in the context of space and time to interrogate tumour microenvironment (TME) impact on therapy response

Location: Vlaams Instituut voor Biotechnologie, Belgium

Principle Investigator: Prof Diether Lambrechts

Collaborators: Dr Jurgen del Favero (Agilent Technologies, Belgium)

Project 12: Interrogating intratumoural heterogeneity and disease resistance mechanisms by scRNA-Seq in intracranial human GBM PDX models

Location: Luxembourg Institute of Health, Luxembourg

Principle Investigator: Prof Simone Niclou

Collaborators: Dr Andreas Kremer (Information Technology for Translational Medicine [ITTM], Luxembourg)

Project 13: Integrative genomic analysis of drug resistance in GBM using advanced 2D and 3D models

Location: Erasmus University Rotterdam, The Netherlands

Principle Investigator: Prof Sieger Leenstra

Collaborators: Dr Jos Joore (Pepscope, The Netherlands and Mimetas, The Netherlands)

Project 14: Modelling therapeutic resistance in GBM using multi-omic computational models

Location: geneXplain, Germany

Principle Investigator: Dr Alexander Kel

Collaborators: Dr Martine Lamfers (Erasmus University Rotterdam, The Netherlands), Prof Diether Lambrechts (Vlaams Instituut voor Biotechnologie, Belgium)

Project 15: Systems methods for analysis of heterogeneous GBM datasets towards elucidation of inter-tumoural resistance pathways and therapeutic new targets

Location: ITTM S.A., Luxembourg

Principle Investigator: Dr Andreas Kremer

Collaborators: Prof Diether Lambrechts (Vlaams Instituut voor Biotechnologie, Belgium), Dr Verena Murphy (Cancer Trials Ireland), Dr Martine Lamfers (Erasmus University Rotterdam, The Netherlands)